Fennec Pharmaceuticals Hits Day Low of CAD 10.35 Amid Price Pressure

Fennec Pharmaceuticals, Inc. experienced a significant decline today, with the stock dropping by 9.37% and reaching an intraday low of CAD 10.35. This performance stands in stark contrast to the S&P/TSX 60, which saw a more modest decline of 1.55% on the same day. Over the past week, Fennec's stock has decreased by 11.16%, while its monthly performance shows a decline of 4.08%. Despite a year-over-year increase of 9.76%, the company's long-term performance indicators raise concerns. The stock has underperformed over three years, with a decline of 17.4%, compared to the S&P/TSX 60's impressive gain of 55.18%. Financial metrics reveal a negative book value and a weak long-term fundamental strength, with operating profit growth at a mere 5.44% over the last five years. Fennec's recent financial results indicate challenges, including a significant drop in net sales and a negative net profit. The company's debt servicing capability is also under scrutiny, reflected in a poor EBIT to interest ratio. Overall, Fennec Pharmaceuticals is navigating a challenging market landscape, marked by notable volatility in its stock performance.